Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Cortesi

Showing results (101-110 of 174) with videos related to

Pageof 18
Sort By:
International Journal of Cancer|October 13, 2009
Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumorsPaola Gazzaniga, Giuseppe Naso, Angela Gradilone, et al.
BJU International|February 5, 2010
Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancerAngela Gradilone, Arianna Petracca, Chiara Nicolazzo, et al.
The Oncologist|August 28, 2010
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trialPaolo Pronzato, Enrico Cortesi, Carin C van der Rijt, et al.
Oncotarget|September 29, 2018
Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II studyFrancesca De Felice, Giancarlo D'Ambrosio, Daniela Musio, et al.
Cancer Letters|March 21, 2021
True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signatureChiara Nicolazzo, Ludovic Barault, Salvatore Caponnetto, et al.
Cancer Detection and Prevention|August 1, 2006
A study of the humoral immune response of breast cancer patients to a panel of human tumor antigens identified by phage displayEmiliano Pavoni, Andrea Pucci, Paola Vaccaro, et al.
Lung Cancer (Amsterdam, Netherlands)|December 4, 2003
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancerFederico Cappuzzo, Filippo De Marinis, Fabrizio Nelli, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2008
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findingsMario Mandalà, Sandro Barni, Irene Floriani, et al.
Cancer Chemotherapy and Pharmacology|March 19, 2010
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinomaFotios Loupakis, Gianluca Masi, Lorenzo Fornaro, et al.
Clinical Genitourinary Cancer|June 11, 2019
Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World PopulationGiorgia Peverelli, Alessandra Raimondi, Raffaele Ratta, et al.
Pageof 18

Showing results (101-110 of 174) with videos related to

Sort By:
Pageof 18
International Journal of Cancer|October 13, 2009
Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumorsPaola Gazzaniga, Giuseppe Naso, Angela Gradilone, et al.
BJU International|February 5, 2010
Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancerAngela Gradilone, Arianna Petracca, Chiara Nicolazzo, et al.
The Oncologist|August 28, 2010
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trialPaolo Pronzato, Enrico Cortesi, Carin C van der Rijt, et al.
Oncotarget|September 29, 2018
Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II studyFrancesca De Felice, Giancarlo D'Ambrosio, Daniela Musio, et al.
Cancer Letters|March 21, 2021
True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signatureChiara Nicolazzo, Ludovic Barault, Salvatore Caponnetto, et al.
Cancer Detection and Prevention|August 1, 2006
A study of the humoral immune response of breast cancer patients to a panel of human tumor antigens identified by phage displayEmiliano Pavoni, Andrea Pucci, Paola Vaccaro, et al.
Lung Cancer (Amsterdam, Netherlands)|December 4, 2003
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancerFederico Cappuzzo, Filippo De Marinis, Fabrizio Nelli, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2008
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findingsMario Mandalà, Sandro Barni, Irene Floriani, et al.
Cancer Chemotherapy and Pharmacology|March 19, 2010
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinomaFotios Loupakis, Gianluca Masi, Lorenzo Fornaro, et al.
Clinical Genitourinary Cancer|June 11, 2019
Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World PopulationGiorgia Peverelli, Alessandra Raimondi, Raffaele Ratta, et al.
Pageof 18